As the US healthcare system struggles with a surge in coronavirus infections and mortality, regulators have given an emergency use authorization (EUA) to a second test that can use pooled sampling to speed up testing and reduce use of testing materials. The manufacturer, however, cautions that patients with negative results may need to get re-tested individually.
A week after the US Food and Drug Administration said it had given temporary market authorization to the first pooled...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?